Role of Perampanel in the Management of Pediatric Epilepsies in Asia: Expert Opinion
Journal
Pediatric neurology
Journal Volume
151
Date Issued
2024-02
Author(s)
Chan, Derrick Wei Shih
Gulati, Sheffali
Likasitwattanakul, Surachai
Lim, Byung Chan
Okumura, Akihisa
Sanchez-Gan, Benilda
Wang, Yi
Liu, Kam Tim
Abstract
Management of pediatric epilepsies poses unique challenges around diagnosis, treatment options, comorbidities, and the potential for these factors to interact with processes in the developing brain. In pediatric patients, broad-spectrum antiseizure medications (ASMs) with minimal potential for adverse events (AEs) and limited impact on cognition and behavior are preferred. Perampanel is a first-in-class ASM with broad-spectrum efficacy, a tolerable safety profile, minimal negative impact on cognitive function, and other features that make it a viable treatment option in this patient population. However, evidence and experience of its use in pediatric patients are less extensive than in adult patients. Experts in pediatric epilepsy across the region convened at a series of meetings to discuss the use of perampanel in pediatric patients, including dose optimization, AE prevention and management, and considerations in particular groups. This article summarizes key evidence for perampanel in the pediatric population and consolidates the experts' recommendations for using the ASM in managing pediatric epilepsies.
Subjects
Antiseizure medication; Asia; Pediatric epilepsies; Perampanel; Real-world experience
SDGs
Type
review